SCHEMBL4129152

SCHEMBL4129152

CCC(C(=O)O)c1ccc(NC2=NC(=O)/C(=C\c3cc4ccccc4cc3OCc3ccc(-c4ccccc4)cc3)S2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 6/20 0.46
CISD1 Q9NZ45 1/20 0.36
PTPN1 P18031 3/20 0.36
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 3/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 2/20 0.33
PSEN1 P49768 1/20 0.33
ALOX5 P09917 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
KDM4E B2RXH2 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4129153 1.00 PTP4A3 (0.46) PTP4A3CISD1PTPN1TDP1MEN1
SCHEMBL4128499 0.90 PTP4A3 (0.47) PTP4A3CISD1PTPN1TDP1MEN1
SCHEMBL4128497 0.90 PTP4A3 (0.47) PTP4A3CISD1PTPN1TDP1MEN1
SCHEMBL4134464 0.86 PTP4A3 (0.36) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4134460 0.86 PTP4A3 (0.36) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4635065 0.85 PTP4A3 (0.43) PTP4A3CISD1PTPN1TDP1MEN1
SCHEMBL4122595 0.84 PTP4A3 (0.46) PTP4A3CISD1PTPN1TDP1MEN1
SCHEMBL4122600 0.84 PTP4A3 (0.46) PTP4A3CISD1PTPN1TDP1MEN1
SCHEMBL4132553 0.83 PTP4A3 (0.37) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4132551 0.83 PTP4A3 (0.37) PTP4A3CISD1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTP4A3 26/4885CISD1 3041/4885PTPN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.